PAVmed (NASDAQ:PAVM – Get Rating) and enVVeno Medical (NASDAQ:NVNO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares PAVmed and enVVeno Medical's net margins, return on equity and return on assets.
Get
PAVmed alerts:
| Net Margins | Return on Equity | Return on Assets |
| PAVmed | N/A | -112.81% | -70.55% |
| enVVeno Medical | N/A | -56.38% | -53.02% |
Earnings & Valuation
This table compares PAVmed and enVVeno Medical's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| PAVmed | $500,000.00 | 83.52 | -$50.35 million | ($0.98) | -0.47 |
| enVVeno Medical | N/A | N/A | -$16.53 million | ($2.58) | -1.88 |
enVVeno Medical has lower revenue, but higher earnings than PAVmed. enVVeno Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
PAVmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for PAVmed and enVVeno Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| PAVmed | 0 | 0 | 2 | 0 | 3.00 |
| enVVeno Medical | 0 | 0 | 0 | 0 | N/A |
PAVmed presently has a consensus target price of $4.25, indicating a potential upside of 826.13%. Given PAVmed's higher possible upside, research analysts clearly believe PAVmed is more favorable than enVVeno Medical.
Institutional & Insider Ownership
14.0% of PAVmed shares are held by institutional investors. Comparatively, 23.1% of enVVeno Medical shares are held by institutional investors. 14.6% of PAVmed shares are held by company insiders. Comparatively, 16.3% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
enVVeno Medical beats PAVmed on 6 of the 11 factors compared between the two stocks.
About PAVmed
(Get Rating)
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.
About enVVeno Medical
(Get Rating)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
